OTC Link · Healthcare · Medical Instruments & Supplies
COLOPLAST AS SP/ADR
Coloplast delivered a solid but uninspiring quarter: Q3 EPS met estimates at **$0.10** and revenue was roughly flat year over year at **$1.1B**. Guidance for FY2026 calls for **5-6%** organic growth, suggesting steady execution in medical supplies but no clear acceleration.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-18 | Q3 2026 | 0.10 | 0.10 | +2.00% | $1.14B | ✅ Beat | — | — | — |
| 2026-05-12 | Q2 2026 | 0.09 | 0.10 | +7.78% | $1.11B | ✅ Beat | — | — | — |
| 2026-02-06 |
| Q1 2026 |
| 0.09 |
| 0.09 |
| +0.00% |
| $1.10B |
| ➖ Inline |
| — |
| — |
| — |
| 2025-11-04 | Q4 2025 | — | 0.07 | — | $1.09B | — | — | — | — |
| 2025-08-19 | Q3 2025 | — | 0.06 | — | $1.06B | — | — | — | — |
| 2025-05-06 | Q2 2025 | — | 0.06 | — | $976.6M | — | — | — | — |
| 2025-02-04 | Q1 2025 | 0.08 | 0.07 | -12.50% | $1.00B | ❌ Miss | +0.45% | +0.72% | -4.76% |
| 2024-11-05 | Q4 2024 | — | 0.08 | — | $1.02B | — | — | — | — |
Showing last 8 quarters.